These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 23721058)
21. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. Pawlak K; Pawlak D; Mysliwiec M Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567 [TBL] [Abstract][Full Text] [Related]
22. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients. Pawlak K; Pawlak D; Myśliwiec M Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748 [TBL] [Abstract][Full Text] [Related]
23. Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema. Hilty MP; Zügel S; Schoeb M; Auinger K; Dehnert C; Maggiorini M Mediators Inflamm; 2016; 2016():1942460. PubMed ID: 27378823 [TBL] [Abstract][Full Text] [Related]
24. Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients. Kaysen GA; Levin NW; Mitch WE; Chapman AL; Kubala L; Eiserich JP Blood Purif; 2006; 24(5-6):508-16. PubMed ID: 17077623 [TBL] [Abstract][Full Text] [Related]
25. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis. Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906 [TBL] [Abstract][Full Text] [Related]
26. Vascular cell adhesion molecule 1, soluble Fas and hepatocyte growth factor as predictors of mortality in nonagenarians: the Vitality 90+ study. Kämppä N; Mäkelä KM; Lyytikäinen LP; Peltonen N; Hautamäki J; Seppälä I; Mononen N; Goebeler S; Karhunen PJ; Hervonen A; Hurme M; Jylhä M; Lehtimäki T Exp Gerontol; 2013 Nov; 48(11):1167-72. PubMed ID: 23911532 [TBL] [Abstract][Full Text] [Related]
33. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Persson M; Engström G; Björkbacka H; Hedblad B Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508 [TBL] [Abstract][Full Text] [Related]
34. [Analysis of selected inflammatory markers in patients with stable renal graft (RTx) 36 months after transplantation]. Krzanowski M; Stompór T; Kuśnierz-Cabala B; Ignacak E; Sułowicz W; Naskalski JW Przegl Lek; 2006; 63(8):597-601. PubMed ID: 17441364 [TBL] [Abstract][Full Text] [Related]
35. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD. Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636 [TBL] [Abstract][Full Text] [Related]
36. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Haugaard SB; Andersen O; Hansen TW; Eugen-Olsen J; Linneberg A; Madsbad S; Olsen MH; Jørgensen T; Borch-Johnsen K; Jeppesen J Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462 [TBL] [Abstract][Full Text] [Related]